Aiolos Bio, Inc.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

It has been less than three years since Atlas Venture closed its thirteenth venture capital fund and one thing is unchanged with its fourteenth – the size of the fund. Atlas announced on 5 December th

PureTech Health plc, after the multibillion-dollar success of its last neuropsychiatry venture Karuna Therapeutics Inc., launched Seaport Therapeutics in April with $100m in series A funding and on 21